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Background: Pyrazole and pyrazolone motifs are well known for their wide range of biological activities such as
antimicrobial, anti-inflammatory, and antitumor activities. The incorporation of more than one pharmacophore in a
single scaffold is a well known approach for the development of more potent drugs. In the present investigation, a
series of differently substituted 4-arylidene pyrazole derivatives bearing pyrazole and pyrazolone pharmacophores in
a single scaffold was synthesized.
Results: The synthesis of novel 4-arylidene pyrazole compounds is achieved through Knovenagel condensation
between 1,3-diaryl-4-formylpyrazoles and 3-methyl-1-phenyl-1H-pyrazol-5-(4H)-ones in good yields. All compounds
were evaluated for their in vitro antimicrobial activity.
Conclusions: A series of 4-arylidene pyrazole derivatives was evaluated for their in vitro antimicrobial activity against
two Gram-positive (Bacillus subtilis and Staphylococcus aureus) and two Gram-negative bacteria (Pseudomonas
fluorescens and Escherichia coli), as well as two pathogenic fungal strains (Candida albicans and Saccharomyces
cerevisiae). The majority of the compounds displayed excellent antimicrobial profile against the Gram-positive (B. subtilis
and S. aureus), and some of them are even more potent than the reference drug ciprofloxacin.
Keywords: Pyrazole; Pyrazolone; Antibacterial activity; Antifungal activity; SulfonamideBackground
Over the years, excessive use of antimicrobial drugs has
led to a worldwide phenomenon of antibacterial resist-
ance. This has resulted into an increase in morbidity and
mortality, and has become a worldwide health issue. As
a consequence, the development of new antimicrobial
agents is in constant demand. The compounds bearing
pyrazole nucleus are well known to exhibit versatile range
of biological activities such as antimicrobial [1-4], anti-
inflammatory [5-7], antidepressant [8], antiviral [9], and
antitumor activities [10]. Among these, 4-functionalized
pyrazoles occupy a unique position in medicinal chemistry
because of their association with antimicrobial [11], anti-
inflammatory [12], antiparasitic [13], and antitumor activ-
ities [14]. Pyrazol-5-(4H)-one also constitutes the core
scaffold of various biologically active synthetic heterocyclic
compounds which have been associated with some inter-
esting pharmaceutical properties, including analgesic [15],
antimicrobial [16,17], anti-inflammatory [18], antitumor* Correspondence: pksharma@kuk.ac.in
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in any medium, provided the original work is p[19], and cytotoxicity [20] properties. Understanding that
the incorporation of both pyrazole and pyrazolone to-
gether in the same scaffold could provide novel com-
pounds with interesting biological activities coupled with
our continuing research interest in the field of 4-
functionalized pyrazole derivatives [12,21-23] and other
biologically active synthetic heterocyclic compounds
[24-27], we set out to undertake the synthesis of some
novel 4-arylidene pyrazole derivatives bearing benzenesul-
fonamide moiety at the N1-position of the pyrazole ring
(Scheme 1) as potential antimicrobial agents.
Methods
In vitro antibacterial activity
The agar well diffusion method [28] was used for the de-
termination of antimicrobial activity of all the synthe-
sized compounds. Overnight broth culture of the
respective bacterial strains was adjusted to approxi-
mately 108 colony forming units (CFU/mL) with sterile
distilled water, and 100 μL of diluted inoculum was
spread over the petriplates containing 25 mL of nutrient
agar media. Eight wells (8 mm in diameter) were maden Open Access article distributed under the terms of the Creative Commons
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Scheme 1 Synthesis of 4-arylidene pyrazole derivatives 4 and 5.
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borer. The test compounds were dissolved in dimethyl-
sulfoxide (DMSO) and then the antimicrobial effect of
the synthesized compounds was evaluated. The wells
were filled with 100 μL of the test compound having a
concentration of 4.0 mg/mL. The plates were incubated
at 37°C for 48 h. The antimicrobial activity was evaluated
by measuring the zone of growth inhibition of bacteria
surrounding the wells after 24 and 48 h. Ciprofloxacin (4.0
mg/mL) served as the antibacterial control. DMSO was
taken as the negative control which did not produce any
significant zone of inhibition.
Determination of minimum inhibitory concentration
The minimum inhibitory concentration (MIC) against the
tested bacteria was determined using the macrodilution
tube method [29] as recommended by NCCLS (2000).
The MIC is the lowest concentration of an antimicrobial
compound, which will inhibit the visible growth of a
microorganism after an overnight incubation. The MIC of
each compound giving an inhibitory zone at a concentra-
tion of 4 mg/mL was also tested with the agar well diffu-
sion method. Different concentrations (4,000 to 0.004 μg/
mL) of a single compound were applied to the number of
wells in the agar plates. The determinations were per-
formed in triplicates, and the results were averaged.
In vitro antifungal activity
The agar well diffusion method was used for the deter-
mination of antimicrobial activity of the compounds.
Overnight broth culture of the respective fungal strains
was adjusted to approximately 108 CFU/mL with sterile
distilled water, and 100 μL of diluted inoculum was spread
over the petriplates containing 25 mL of Sabouraud's dex-
trose agar media (pH 5.6). Eight wells (8 mm in diameter)
were made equidistant with each of the plates using a ster-
ile cork borer. The test compounds were dissolved inDMSO and then the antimicrobial effect of the test com-
pounds was tested. The wells were filled with 100 μL of
the test compound having a concentration 4 mg/mL. The
plates were incubated at 30°C for 48 to 72 h. The anti-
microbial activity was evaluated by measuring the zone of
growth inhibition of fungi surrounding the wells after 48
and 72 h. Fluconazole (4 mg/mL) served as the antifungal
control. DMSO was taken as the negative control which
did not produce any significant zone of inhibition. The ex-
periments were performed in triplicates. The diameter of
the fungal colonies was measured.
Results and discussion
Chemistry
The synthetic route used to synthesize the target 4-
arylidene pyrazole derivatives (4 and 5) is outlined in
Scheme 1. 4-Formyl pyrazoles (2) were synthesized using
our earlier reported procedure [21], while 3-methyl-1-
aryl-1H-pyrazol-5-(4H)-ones (3) was prepared by conden-
sation of ethylacetoacetate with appropriate hydrazine
[30,31]. Finally, base-catalyzed Knoevenagel condensation
of appropriately substituted pyrazol-5-(4H)-ones (3) with
various substituted 4-formylpyrazoles (2) in ethanol con-
taining catalytic amount of triethylamine afforded the tar-
get 4-arylidene pyrazole derivatives (4 and 5) in good
yield. Spectral data (IR, 1H NMR, and mass) of the newly
synthesized compounds 4a-g and 5a-g were in full agree-
ment with the proposed structures. In the 1H NMR spec-
tra of 4 and 5, the C=CH proton displayed more
downfield signal in the range δ 10.18 to 10.25. Besides this,
C5-H of the pyrazole ring resonates at around δ 7.51 to
7.63. The IR spectra of 4 and 5 showed a characteristic ab-
sorption band around 1,674 to 1,682 cm−1 that was
assigned to the C=O stretching, while the two absorptions
bands around 1,304 to 1,335 and 1,149 to 1,165 cm−1
which further supported the proposed structures of newly
synthesized compounds displayed the SO2 stretchings.
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In vitro antibacterial activity
All the synthesized compounds (4 and 5) were screened
for their in vitro antibacterial activity against the four
pathogenic bacteria, Bacillus subtilis (microbial-type cul-
ture collection (MTCC) 121) and Staphylococcus aureus
(MTCC 96) representing the Gram-positive bacteria, and
Pseudomonas fluorescens (MTCC 1749) and Escherichia
coli (MTCC 1652) representing the Gram-negative bac-
teria (Table 1), by agar well diffusion method [28] using
ciprofloxacin as the reference drug. The MIC measure-
ments were performed using a macrodilution method [29]
(Table 1).
The results revealed that all the tested compounds
showed variable antibacterial activity against the Gram-
positive as well as the Gram-negative bacteria. Among
the tested compounds, the antibacterial activity of com-
pounds 4a and 5a with a zone of inhibition of 28 mm
(MIC 0.04 μg/mL) was found to be better than that of
the reference drug ciprofloxacin with a zone of inhib-
ition of 26 mm (MIC 0.4 μg/mL) against B. subtilis.
Compounds 4f and 5d also displayed appreciable activity
with a zone of inhibition of 24 mm (MIC 0.4 μg/mL)
and 22 mm (MIC 4.0 μg/mL), respectively, against B.
subtilis. Compound 5a with two sulfonamide groups was
found to be the most effective against S. aureus, showing
a maximum zone of inhibition of 30 mm (MIC 0.04 μg/
mL). 4a also showed antibacterial activity with a zone of
inhibition of 26 mm (MIC 0.4 μg/mL) comparable to the
reference drug ciprofloxacin with a zone of inhibition of
26 mm (MIC 0.4 μg/mL) against S. aureus. Six moreTable 1 In vitro antibacterial activity and MIC of compounds
Compounda Diameter
B. subtilis S. aure
4a 28 ± 0.00 (0.04) 26 ± 0.30
4b 20 ± 0.19 (4.0) 24 ± 0.50
4c 16 ± 0.19 (40) 24 ± 0.32
4d 16 ± 0.00 (40) 12 ± 0.19
4e 12 ± 0.40 (400) 16 ± 0.22
4f 24 ± 0.07 (0.4) 20 ± 0.37
4g 14 ± 0.23 (400) 12 ± 0.10
5a 28 ± 0.09 (0.04) 30 ± 0.15
5b 16 ± 0.32 (40) 25 ± 0.42
5c 14 ± 0.18 (400) 22 ± 0.24
5d 22 ± 0.09 (4.0) 22 ± 0.20
5e 14 ± 0.00 (400) 16 ± 0.00
5f 12 ± 0.33 (400) 16 ± 0.36
5g 14 ± 0.32 (400) 12 ± 0.30
Ciprofloxacin 26 ± 0.025 (0.4) 26 ± 0.45
MIC (μg/mL), minimum inhibitory concentration. Hyphens denote no activity. aThe
(8 mm), are means of the three replicates.compounds (4b-c, 4f, and 5b-d) were found to possess
appreciable antibacterial activity with a zone of inhib-
ition greater than 20 mm against S. aureus. Interestingly,
compounds 4a and 5a, both with an unsubstituted
phenyl ring at C-3 of pyrazole, displayed a tenfold MIC
(0.04 μg/mL) better than the standard drug ciprofloxacin
against B. subtilis. A comparison within each series sug-
gested that any substituent on the phenyl ring placed at
the 3-position of the pyrazole moiety has a negative ef-
fect on the antibacterial activity against Gram-positive
bacteria, as best results were seen with the naked phenyl
ring in each series (compare 4a with 4a-g, and 5a with
5a-g; Table 1). No definite trend was discernable that
could lead to draw a correlation of the activities between
series 4 and 5.
Against Gram-negative bacteria (P. fluorescens), only
compound 5e showed a significant activity with a zone
of inhibition of 25 mm (MIC 0.4 μg/mL) comparable to
the standard drug ciprofloxacin (zone of inhibition 23
mm), albeit with a tenfold better MIC. Against E. coli,
five compounds (4e, 4g 5a, 5d, and 5g) showed good
antibacterial activity with a zone of inhibition of 20 mm.
However, none of the compounds were found to be as
effective as the standard drug ciprofloxacin against E.
coli (Table 1). Thus, it can be concluded that the synthe-
sized compounds are more effective against the Gram-
positive bacteria than the Gram-negative bacteria.
In vitro antifungal activity
All the synthesized compounds were also evaluated for
their in vitro antifungal activity against the two pathogenic4 and 5 using agar well diffusion method
of zone of inhibition in mm (MIC)b
us P. fluorescens E. coli
(0.4) 14 ± 0.08 (400) 14 ± 0.46 (400)
(0.4) 15 ± 0.09 (400) 14 ± 0.23 (400)
(0.4) - 14 ± 0.23 (400)
(400) - 14 ± 0.43 (400)
(40) - 20 ± 0.30 (4)
(4.0) 14 ± 0.14 (400) 18 ± 0.33 (40)
(400) - 20 ± 0.34 (4)
(0.04) - 20 ± 0.32 (4)
(0.4) 16 ± 0.12 (40) 14 ± 0.50 (400)
(40) 18 ± 0.54 (40)
(4.0) 16 ± 0.23 (40) 20 ± 0.12 (4)
(40) 25 ± 0.13 (0.4) 18 ± 0.23 (40)
(40) - 16 ± 0.43 (40)
(400) 14 ± 0.43 (400) 20 ± 0.21 (4)
(0.4) 23 ± 0.42 (4.0) 25 ± 0.44 (0.4)
concentration is 4.0 mg/mL. bThe values, including the diameter of the well
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romyces cerevisiae (MTCC 170) by agar well diffusion
method (Table 2). Fluconazole was used as the reference
drug. Most of the tested compounds in each series (4 and
5) showed moderate to good antifungal activity. Com-
pound 4g was found to be as effective as the standard
drug, with a zone of inhibition of 16 mm against C.
albicans. Against S. cerevisiae, 4a and 5b (zone of inhib-
ition 28 mm) were found to be the most effective and were
better than the standard drug fluconazole (zone of inhib-
ition 24 mm), while the three other compounds (4d, 5e,
and 5g) were found to possess good antifungal activity.
Interestingly, some of the newly synthesized compounds
(4a, 5b, 5e, and 5g) showed multifold reduction in the
MIC values against S. cerevisiae, making the new deriva-
tives attractive agents for further evaluation.
Experimental
The melting points were determined in open capillaries
in an electrical apparatus and were uncorrected. The IR
spectra in KBr were recorded with the ABB MB3000
DTGS IR instrument. The 1H NMR spectra were
recorded on Bruker instrument (Bruker Scientific Instru-
ments, MA, USA) at 300 MHz, taking DMSO-d6 as the
solvent. The chemical shifts are expressed in δ, ppm.
The mass spectra (DART-MS) were recorded on a JEOL
AccuTOF JMS-T100LC mass spectrometer having a dir-
ect analysis in real time (DART) source in the ES+ mode.
The purity of the compounds was checked using 1HTable 2 In vitro antifungal activity and MIC of compounds
4 and 5 using agar well diffusion method
Compounda Diameter of zone of inhibition in mm (MIC)b
Candida albicans Saccharomyces cerevisiae
4a 12 ± 0.43 (400) 28 ± 0.15 (0.04)
4b 12 ± 0.56 (400) 16 ± 0.38 (40)
4c 12 ± 0.54 (400) 16 ± 0.40 (40)
4d 14 ± 0.14 (400) 20 ± 0.45 (4.0)
4e 12 ± 0.45 (400) 18 ± 0.16 (40)
4f 12 ± 0.32 (400) 16 ± 0.27 (40)
4g 16 ± 0.27 (40) 18 ± 0.48 (40)
5a 12 ± 0.32 (400) 16 ± 0.00 (40)
5b 12 ± 0.33 (400) 28 ± 0.28 (0.04)
5c - 16 ± 0.00 (40)
5d 12 ± 0.23 (400) 18 ± 0.18 (40)
5e 13 ± 0.37 (400) 22 ± 0.44 (4.0)
5f - 16 ± 0.30 (40)
5g 12 ± 0.43 (400) 20 ± 0.10 (4.0)
Fluconazole 16 ± 0.45 (40) 24 ± 0.50 (40)
MIC (μg/mL), minimum inhibitory concentration. Hyphen denotes no activity.
aThe concentration is 4.0 mg/mL. bThe values, including the diameter of the
well (8 mm), are means of the three replicates.NMR and thin layer chromatography on silica gel plates,
using a mixture of petroleum ether and ethyl acetate as
the eluent. Iodine or UV lamp was used as a visualizing
agent. In the following section, these abbreviations are
used: ‘s’ for singlet, ‘m’ for multiplet, and ‘ex’ for ex-
changeable proton are used for the NMR assignments;
‘s’ for strong and ‘m’ for medium are used for the IR
assignments.General procedure for the conversion of 4-formylyrazole
into 4-arylidene pyrazole derivatives (4 and 5)
To a solution of 4-formylpyrazoles, compound 2 (1 mmol)
in ethanol was added to the appropriate pyrazolone 3
(1 mmol) followed by a catalytic amount of triethylamine
and refluxed the resulting reaction mixture for 6 to 7 h.
After the completion of the reaction, the solution was re-
duced to 1/4 of its volume and cooled to room
temperature. The solid separated out was filtered, washed
with water (100 mL) followed by cold ethanol (10 mL),
and crystallized from ethanol to afford the target com-
pounds 4 and 5.4-{4-[(3-methyl-5-oxo-1-phenyl-1,5-dihydro-4H-pyrazol-4-
ylidene)methyl]-3-phenyl-1H-pyrazol-1-yl}
benzenesulfonamide (4a)
M.p. 272°C to 275°C, yield 73%; IR (KBr, cm−1): 3,356,
3,267, and 3,256 (m, N-H stretch), 1,674 (s, C=O
stretch), 1,589 (s, C=N stretch), 1,497 (s, N-H bend),
1,311 and 1,157 (s, SO2 stretch);
1H NMR (300 MHz,
DMSO-d6): δ 10.23 (s, 1H, C=CH), 8.13 (d, 2H, J = 7.5
Hz, Ar-H), 8.04 (d, 2H, J = 8.4 Hz, Ar-H), 7.95 (d, 2H, J =
8.4 Hz, Ar-H), 7.77 to 7.80 (m, 2H, Ar-H), 7.60 to 7.62 (m,
3H, pyrazole C5-H, Ar-H), 7.52 (s, ex, 2H, SO2NH2), 7.46
(t, 2H, J = 7.5 Hz, Ar-H), 7.21 to 7.23 (m, 1H, Ar-H), 2.23






M.p. 158°C to 160°C, yield 74%; IR (KBr, cm−1): 3,742,
3,272, and 3,126 (m, N-H stretch), 1,682 (s, C=O
stretch), 1,589 (s, C=N stretch), 1,497 (s, N-H bend),
1,319 and 1,149 (s, SO2 stretch);
1H NMR (300 MHz,
DMSO-d6): δ 10.23 (s, 1H, C=CH), 8.14 (d, 2H, J = 8.7
Hz, Ar-H), 8.04 (d, 2H, J = 8.7 Hz, Ar-H), 7.95 (d, 2H,
J = 7.8 Hz, Ar-H), 7.68 (d, 2H, J = 7.8 Hz, Ar-H), 7.53
to 7.54 (m, 3H, pyrazole C5-H, SO2NH2), 7.47 (d, 2H,
J = 7.8 Hz, Ar-H), 7.43 (d, 2H, J = 7.5 Hz, Ar-H),
7.21 to 7.24 (m, 1H, Ar-H), 2.43 (s, 3H, CH3), 2.25








M.p. 156°C to 158°C, yield 76%; IR (KBr, cm−1): 3,372,
3,271, and 3,123 (m, N-H stretch), 1,674 (s, C=O
stretch), 1,597 (s, C=N stretch), 1,504 (s, N-H bend),
1,319 and 1,157 (s, SO2 stretch);
1H NMR (300 MHz,
DMSO-d6): δ 10.24 (s, 1H, C=CH), 8.15 (d, 2H, J = 8.1
Hz, Ar-H), 8.04 (d, 2H, J = 7.8 Hz, Ar-H), 7.97 (d, 2H, J =
7.5 Hz, Ar-H), 7.74 (d, 2H, J = 7.8 Hz, Ar-H), 7.55 (s, 1H,
pyrazole C5-H), 7.52 (s, ex, 2H, SO2NH2), 7.48 (d, 2H, J =
8.1 Hz, Ar-H), 7.16 to 7.22 (m, 3H, Ar-H), 3.87 (s, 3H,







M.p. 258°C to 260°C, yield 74%; IR (KBr, cm−1): 3,333,
3,225, and 3,132 (m, N-H stretch), 1,674 (s, C=O
stretch), 1,597 (s, C=N stretch), 1,504 (s, N-H bend),
1,311 and 1,157 (s, SO2 stretch);
1H NMR (300 MHz,
DMSO-d6): δ 10.25 (s, 1H, C=CH), 8.16 (d, 2H, J = 8.4
Hz, Ar-H), 8.05 (d, 2H, J = 8.7 Hz, Ar-H), 7.96 (d, 2H, J =
8.4 Hz, Ar-H), 7.84 to 7.89 (m, 2H, Ar-H), 7.53 (br s, 3H,
pyrazole C5-H, SO2NH2), 7.44 to 7.46 (m, 4H, Ar-H), 7.20
to 7.24 (m, 1H, Ar-H), 2.28 (s, 3H, CH3); DART MS: m/z





M.p. 236°C to 238°C, yield 74%; IR (KBr, cm−1): 3,372,
3,271, and 3,123 (m, N-H stretch), 1,674 (s, C=O
stretch), 1,589 (s, C=N stretch), 1,497 (s, N-H bend),
1,319 and 1,157 (s, SO2 stretch);
1H NMR (300 MHz,
DMSO-d6): δ 10.23 (s, 1H, C=CH), 8.14 (d, 2H, J = 8.7
Hz, Ar-H), 8.05 (d, 2H, J = 8.7 Hz, Ar-H), 7.95 (d, 2H, J =
8.1 Hz, Ar-H), 7.83 (d, 2H, J = 8.4 Hz, Ar-H), 7.68 (d, 2H,
J = 8.4 Hz, Ar-H), 7.53 (s, ex, 2H, SO2NH2), 7.51 (s, 1H,
pyrazole C5-H), 7.43 (d, 2H, J = 7.8 Hz Ar-H), 7.21 to 7.24
(m, 1H, Ar-H), 2.27 (s, 3H, CH3); DART MS: m/z 518.26/






M.p. 162°C to 165°C, yield 70%; IR (KBr, cm−1): 3,373,
3,261, and 3,123 (m, N-H stretch), 1,682 (s, C=O
stretch), 1,597 (s, C=N stretch), 1,497 (s, N-H bend),
1,311 and 1,157 (s, SO2 stretch);
1H NMR (300 MHz,
DMSO-d6): δ 10.20 (s, 1H, C=CH), 8.11 (d, 2H, J = 8.7
Hz, Ar-H), 8.04 (d, 2H, J = 8.7 Hz, Ar-H), 7.92 to 7.99(m, 3H, Ar-H), 7.80 (d, 2H, J = 8.1 Hz, Ar-H), 7.67 to 7.74
(m, 3H, Ar-H), 7.61 (s, 1H, pyrazole C5-H), 7.54 (s, ex, 2H,
SO2NH2), 7.20 to 7.26 (m, 1H, Ar-H), 2.24 (s, 3H, CH3);






M.p. 310°C to 312°C, yield 73%; IR (KBr, cm−1): 3,371,
3,271, and 3,124 (m, N-H stretch), 1,674 (s, C=O stretch),
1,589 (s, C=N stretch), 1,497 (s, N-H bend), 1,335 and
1,157 (s, SO2 stretch);
1H NMR (300 MHz, DMSO-d6): δ
10.23 (s, 1H, C=CH), 8.44 (d, 2H, J = 8.4 Hz, Ar-H), 8.16
(d, 2H, J = 8.4 Hz, Ar-H), 8.04 to 8.11 (m, 4H, Ar-H), 7.94
(d, 2H, J = 7.8 Hz, Ar-H), 7.56 (s, 1H, pyrazole C5-H), 7.54
(s, ex, 2H, SO2NH2), 7.43 to 7.48 (m, 2H, Ar-H), 7.21 to
7.30 (m, 1H, Ar-H), 2.29 (s, 3H, CH3); DART MS: m/z





M.p. 248°C to 252°C, yield 73%; IR (KBr, cm−1): 3,340,
3,271, and 3,217 (m, N-H stretch), 1,674 (s, C=O
stretch), 1,589 (s, C=N stretch), 1,504 (s, N-H bend),
1,335 and 1165 (s, SO2 stretch);
1H NMR (300 MHz,
DMSO-d6): δ 10.21 (s, 1H, C=CH), 8.14 to 8.19 (m, 4H,
Ar-H), 8.05 (d, 2H, J = 8.4 Hz, Ar-H), 7.91 (d, 2H, J = 8.7
Hz, Ar-H), 7.79 to 7.80 (m, 2H, Ar-H), 7.59 to 7.63 (m,
4H, pyrazole C5-H, Ar-H), 7.54 (s, ex, 2H, SO2NH2), 7.36
(s, ex, 2H, SO2NH2), 2.28 (s, 3H, CH3); DART MS: m/z





M.p. 282°C to 285°C, yield 75%; IR (KBr, cm−1): 3,340,
3,248 (m, N-H stretch), 1,682 (s, C=O stretch), 1,589 (s,
C=N stretch), 1,497 (s, N-H bend), 1,304 and 1,149 (s,
SO2 stretch);
1H NMR (300 MHz, DMSO-d6): δ 10.19
(s, 1H, C=CH), 8.13 to 8.19 (m, 4H, Ar-H), 8.05 (d,
2H, J = 8.4 Hz, Ar-H), 7.92 (d, 2H, J = 8.4 Hz, Ar-H),
7.68 (d, 2H, J = 7.8 Hz, Ar-H), 7.58 (s, 1H, pyrazole
C5-H), 7.52 (s, ex, 2H, SO2NH2), 7.42 (d, 2H, J = 7.5
Hz, Ar-H), 7.34 (s, ex, 2H, SO2NH2), 2.43 (s, 3H, CH3),







M.p. 320°C to 326°C, yield 74%; IR (KBr, cm−1): 3,317,
3,232, 3,148 and 3,086 (m, N-H stretch), 1,674 (s, C=O
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1,335 and 1157 (s, SO2 stretch);
1H NMR (300 MHz,
DMSO-d6): δ 10.18 (s, 1H, C=CH), 8.12 to 8.19 (m, 4H,
Ar-H), 8.04 (d, 2H, J = 8.7 Hz, Ar-H), 7.91 (d, 2H, J = 8.7
Hz, Ar-H), 7.73 (d, 2H, J = 8.7 Hz, Ar-H), 7.57 (s, 1H,
pyrazole C5-H), 7.53 (s, ex, 2H, SO2NH2), 7.36 (s, ex, 2H,
SO2NH2), 7.16 (d, 2H, J = 8.4 Hz, Ar-H), 3.86 (s, 3H,







M.p. 208°C to 210°C, yield 71%; IR (KBr, cm−1): 3,317,
3,202, 3,148 and 3,070 (m, N-H stretch), 1,674 (s, C=O
stretch), 1,589 (s, C=N stretch), 1,504 (s, N-H bend),
1,335 and 1,157 (s, SO2 stretch);
1H NMR (300 MHz,
DMSO-d6): δ 10.20 (s, 1H, C=CH), 8.14 to 8.19 (m, 4H,
Ar-H), 8.05 (d, 2H, J = 8.7 Hz, Ar-H), 7.91 (d, 2H, J =
8.7 Hz, Ar-H), 7.86 (dd, 2H, J = 8.1, 5.4 Hz Ar-H), 7.55
(br s, 3H, pyrazole C5-H, SO2NH2), 7.43 to 7.49 (m, 2H,
Ar-H), 7.37 (s, ex, 2H, SO2NH2), 2.29 (s, 3H, CH3);






M.p. 318°C to 320°C, yield 72%; IR (KBr, cm−1): 3,340,
3,256, 3,148 and 3,086 (m, N-H stretch), 1,682 (s, C=O
stretch), 1,597 (s, C=N stretch), 1,497 (s, N-H bend),
1,335 and 1,157 (s, SO2 stretch);
1H NMR (300 MHz,
DMSO-d6): δ 10.20 (s, 1H, C=CH), 8.15 to 8.19 (m, 4H,
Ar-H), 8.06 (d, 2H, J = 8.4 Hz, Ar-H), 7.92 (d, 2H, J =
8.7 Hz, Ar-H), 7.84 (d, 2H, J = 8.1 Hz, Ar-H), 7.68 (d,
2H, J = 8.1 Hz, Ar-H), 7.58 (s, 1H, pyrazole C5-H), 7.54
(s, ex, 2H, SO2NH2), 7.36 (s, ex, 2H, SO2NH2), 2.31 (s,
3H, CH3); DART MS: m/z 597.25/599.25 [M + H]
+/[M +





M.p. 330°C to 332°C, yield 69%; IR (KBr, cm−1): 3,742,
3,333 and 3,256 (m, N-H stretch), 1,682 (s, C=O
stretch), 1,597 (s, C=N stretch), 1,497 (s, N-H bend),
1,335 and 1,157 (s, SO2 stretch);
1H NMR (300 MHz,
DMSO-d6): δ 10.19 (s, 1H, C=CH), 8.15 to 8.19 (m, 4H,
Ar-H), 8.06 (d, 2H, J = 8.4 Hz, Ar-H), 7.92 (d, 2H, J =
8.4 Hz, Ar-H), 7.82 (d, 2H, J = 7.8 Hz, Ar-H), 7.76 (d,
2H, J = 7.8 Hz, Ar-H), 7.57 (s, 1H, pyrazole C5-H), 7.54
(s, ex, 2H, SO2NH2), 7.35 (s, ex, 2H, SO2NH2), 2.31 (s,
3H, CH3); DART MS: m/z 641.19/643.20 [M + H]
+/[M +




M.p. 298°C to 300°C, yield 71%; IR (KBr, cm−1): 3,348,
3,248, 3,132 and 3,109 (m, N-H stretch), 1,682 (s, C=O
stretch), 1,589 (s, C=N stretch), 1,528 (s, N-H bend),
1,335 and 1,157 (s, SO2 stretch);
1H NMR (300 MHz,
DMSO-d6): δ 10.21 (s, 1H, C=CH), 8.45 (d, 2H, J = 8.4
Hz, Ar-H), 8.16 to 8.19 (m, 4H, Ar-H), 8.11 (d, 2H, J =
9.0 Hz, Ar-H), 8.07 (d, 2H, J = 8.7 Hz, Ar-H), 7.92 (d,
2H, J = 8.7 Hz, Ar-H), 7.62 (s, 1H, pyrazole C5-H), 7.55
(s, ex, 2H, SO2NH2), 7.36 (s, ex, 2H, SO2NH2), 2.33 (s,




In conclusion, we have presented the novel 4-arylidene
pyrazole derivatives bearing benzenesulfonamide moiety
as potential antimicrobial agents. The reported com-
pounds were conveniently prepared by Knovenagel con-
densation of 4-formyl pyrazoles with pyrazolones. Some
of the tested compounds displayed excellent antibacterial
properties against Gram-positive bacteria (B. subtilis and
S. aureus). For instance, compounds 4a and 5a were
found to be more effective than the reference drug cip-
rofloxacin. However, against Gram-negative bacteria (P.
fluorescens and E. coli), the level of activity shown by the
tested compounds was found to be significantly low as
only 2 of the 14 tested compounds displayed activities
comparable to the reference drug against P. fluorescens,
while none of the compounds were found to be highly
effective against E. coli. All the tested compounds
showed moderate antifungal activity against C. albicans,
while two compounds showed activity better than the
reference drug against S. cerevisiae. In short, the
reported compounds showed remarkable potential as
antimicrobial agents and warranted further investigation
of their mechanism of actions and binding site. The
studies regarding these aspects are being planned with
the help of a prospective collaborator.
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